ImmuPharma PLC has initiated regulatory steps to move its Kapiglucagon drug for Type 1 diabetes into human trials in the US. The company is working with tranScrip Limited to prepare for a pre-IND meeting with the FDA, aiming to use an accelerated 505(b)(2) approval pathway that leverages existing data from native glucagon. Kapiglucagon is designed for dual-hormone artificial pancreas systems, potentially improving blood sugar management over current insulin-only pumps. This move supports ImmuPharma's strategy to advance the drug efficiently towards clinical testing and future partnerships.
The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...
Corbin Advisors' Q2 2026 survey shows industrial investor sentiment at its highest in five years, with 84% of participants bullish or neutral-to-bullish due to strong order momentum and demand from data centers and AI sectors. Expectations for Q2 rev...
Bitcoin and XRP prices remained steady near critical support levels as investors awaited discussions on the CLARITY Act, a significant crypto regulation bill. The broader crypto market dipped 1.35%, with Bitcoin around $64,000 and XRP just above $1.1...
Vista Energy aims to grow production to over 200,000 barrels of oil equivalent per day by 2028 through organic growth and strategic acquisitions. The company focuses on low operating costs and self-funded expansion, achieving an EBITDA run rate above...
Tether's USDT stablecoin is rapidly expanding, adding over 30 million new wallets each quarter and reaching about 500 million wallets globally, driven largely by demand in emerging markets. This growth reflects USDT's role as a financial tool for rem...
